B. Douglas Smith, MD, Professor of Oncology at Johns Hopkins University, Baltimore, MD, recommends tools and strategies to minimize toxicities from tyrosine kinase inhibitor (TKI) treatment of patients with CML. Dr Smith discusses the side effect profiles of existing and emerging TKIs, the importance of monitoring patient response, dosing options, and guidelines for discontinuation or dose de-escalation of TKIs.